Early Tests of Maraviroc as Microbicide Produce Less Activity Than Expected (July 23, 2009)
Preclinical ex-vivo tests of the entry inhibitor drug maraviroc as a possible microbicide have found that the drug only produced a moderate protective effect against HIV: a 50% to 60% inhibition of HIV infection of penile tissue and an 85% inhibition in colorectal tissue, when given at high doses.
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.